eCite Digital Repository

Airway cell and cytokine changes in early asthma deterioration after inhaled corticosteroid reduction

Citation

Khor, YH and Feltis, BN and Reid, DW and Ward, C and Johns, DP and Wood-Baker, R and Walters, EH, Airway cell and cytokine changes in early asthma deterioration after inhaled corticosteroid reduction, Clinical and Experimental Allergy, 37, (8) pp. 1189-1198. ISSN 0954-7894 (2007) [Refereed Article]

DOI: doi:10.1111/j.1365-2222.2007.02762.x

Abstract

Background: Back-titration of inhaled corticosteroid (ICS) dose in well-controlled asthma patients is emphasized in clinical guidelines, but there are few published data on the airway cell and cytokine changes in relation to ICS reduction. In our study, 20 mild-to-moderate persistent (inspite of low-moderate dose ICS treatment) asthmatic subjects prospectively rendered largely asymptomatic by high-dose ICS were assessed again by clinical, physiological, and airway inflammatory indices after 4-8 weeks of reduced ICS treatment. We aimed at assessing the underlying pathological changes in relation to clinical deterioration. Methods: Patients recorded daily symptom scores and peak expiratory flows (PEF). Spirometry and airways hyperreactivity (AHR) were measured and bronchoscopy was performed with assessment of airway biopsies (mast cells, eosinophils, neutrophils, and T lymphoctyes), bronchoalveolar lavage (BAL) IL-5 and eotaxin levels and cellular profiles at the end of high-dose ICS therapy and again after ICS dose reduction. Baseline data were compared with symptomatic steroid-free asthmatics (n=42) and non-asthmatic controls (n=28). Results: After ICS reduction, subjects experienced a variable but overall significant increase in symptoms and reductions in PEF and forced expiratory volume in 1 s. There were no corresponding changes in AHR or airways eosinophilia. The most relevant pathogenic changes were increased CD4 +/CD8 + T cell ratio, and decreased sICAM-1 and CD18 macrophage staining (potentially indicating ligand binding). However, there was no relationship between the spectrum of clinical deterioration and the changes in cellular profiles or BAL cytokines. Conclusions: These data suggest that clinical markers remain the most sensitive measures of early deterioration in asthma during back-titration of ICS, occurring at a time when AHR and conventional indices of asthmatic airway inflammation appear unchanged. These findings have major relevance to management and to how back-titration of ICS therapy is monitored. © 2007 Blackwell Publishing Ltd.

Item Details

Item Type:Refereed Article
Research Division:Medical and Health Sciences
Research Group:Cardiorespiratory Medicine and Haematology
Research Field:Respiratory Diseases
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Respiratory System and Diseases (incl. Asthma)
Author:Khor, YH (Dr Yet Khor)
Author:Feltis, BN (Dr Bryce Feltis)
Author:Reid, DW (Dr David Reid)
Author:Johns, DP (Associate Professor David Johns)
Author:Wood-Baker, R (Professor Richard Wood-Baker)
Author:Walters, EH (Professor Haydn Walters)
ID Code:50350
Year Published:2007
Web of Science® Times Cited:6
Deposited By:Menzies Institute for Medical Research
Deposited On:2007-08-01
Last Modified:2009-08-19
Downloads:0

Repository Staff Only: item control page